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Lost	in	translation:	microRNAs	mediate	pathological	cross-talk	between	motor	neurons	
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The	central	nervous	system	is	estimated	to	comprise	over	two	hundred	billion	neurons	and	
glial	 cells.	 The	 crosstalk	 between	 these	 cells	 and	 the	 resultant	 fine-tuning	 of	
neurotransmission	underpins	every	process	 regulated	by	 the	brain	and	spinal	 cord.	We	are	
still	 trying	to	unravel	the	complex	network	of	chemical	signals	that	drives	this	 inter-cellular	
communication.	However,	in	the	past	decade	non-coding	RNAs	have	emerged	as	key	players	
in	 the	 cross-talk	 between	 neurons	 and	 neighbouring	 glial	 cells	 (Schratt,	 2009).	 Non-coding	
RNAs	 are	 a	 class	 of	 untranslated	 RNA	 species	 that	 contribute	 to	 the	 post-transcriptional	
control	 of	 protein	 synthesis	 via	 binding	 and	 subsequent	modulation	 (usually	 inhibition)	 of	
mRNA	 translation.	MicroRNAs	 (miRNAs)	are	part	of	 this	group	of	molecules	and	have	been	
increasingly	implicated	in	inter-cellular	communication	in	health	and	disease.	
	
In	this	issue	of	Brain,	Hoye	and	colleagues	explore	the	function	of	miR-218,	a	motor	neuron-
secreted	 miRNA,	 in	 the	 pathophysiology	 of	 amyotrophic	 lateral	 sclerosis	 or	 motor	 neuron	
disease	(ALS/MND)	(Hoye	et	al.,	2018).	ALS	is	a	neurodegenerative	condition	causing	injury	
and	cell	death	primarily	of	upper	and	lower	motor	neurons,	resulting	in	progressive	failure	of	
the	 neuromuscular	 system,	widespread	muscle	 denervation	 and	 death	 typically	within	 2–5	
years	of	symptom	onset.	ALS	is	a	heterogeneous	and	complex	disease	and	it	has	become	clear	
that	 it	 is	 non-cell	 autonomous	 and	 that	 glial	 cells,	 in	 particular	 astrocytes,	 microglia	 and	
oligodendrocytes,	 contribute	 to	 the	neurodegenerative	process	 (Hardiman	et	al.,	2017).	The	
mechanisms	through	which	glial	activation	contributes	to	motor	neuron	death	and	the	causal	
relationship	between	these	two	events	have	not	yet	been	clearly	defined.			
	
The	 study	 by	 Hoye	 et	 al.	 focuses	 on	 the	 effect	 of	 the	 motor	 neuron-specific	 miR-218	 on	
astrocyte	function	following	its	release	from	dying	motor	neurons.	The	authors	had	identified	
this	miRNA	molecule	in	a	previous	study,	where	they	found	that	miR-218	was	upregulated	10-
fold	in	the	CSF	of	a	rat	model	of	ALS	at	the	end-stage	of	the	disease	(Hoye	et	al.,	2017).	In	this	
issue	 of	 Brain,	 the	 authors	 use	 an	 elegant	 combination	 of	 miRNA	 tagging	 and	 affinity	
purification	to	show	that	 in	vivo	miR-218	is	expressed	predominantly	in	motor	neurons	and	
only	at	very	 low	 levels	within	healthy	or	ALS	mouse	astrocytes,	 concluding	 that	miR-218	 is	
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not	 a	major	 player	 in	 regulating	 protein	 expression	 in	 adult	 astrocytes.	 However,	 using	 in	
silico	 bioinformatics	 tools	 and	 a	 luciferase	 assay,	 the	 authors	 also	 show	 that	 miR-218	
regulates	the	expression	of	the	glutamate	re-uptake	transporter	EAAT2.	This	protein	is	crucial	
for	the	correct	regulation	of	excitatory	glutamatergic	neurotransmission.	It	plays	a	key	role	in	
the	 neuroprotective	 function	 of	 astrocytes	 by	 preventing	 accumulation	 of	 glutamate	 in	 the	
extracellular	synaptic	cleft.	Reduced	expression	or	function	of	EAAT2	leads	to	excitotoxicity,	a	
process	clearly	linked	to	the	pathophysiology	of	ALS	(Rothstein	et	al.,	1995).	
	
By	treating	mouse	astrocytes	with	medium	from	lysed	NSC34	cells,	Hoye	et	al.	show	that	the	
miR-218	 released	 into	 the	medium	 can	 be	 taken	 up	 by	 astrocytes,	 and	 that	 this	 uptake	 is	
associated	 with	 decreased	 expression	 of	 EAAT2.	 Extending	 these	 in	 vitro	 experiments,	 the	
authors	test	their	hypothesis	in	vivo	in	the	gold-standard	G93A	SOD1	transgenic	mouse	model	
of	 ALS.	 Intracerebroventricular	 (ICV)	 injection	 of	 an	 antisense	 oligonucleotide	 against	miR-
218	in	mutant	SOD1	mice	at	 the	symptomatic	stage,	when	motor	neurons	appear	to	release	
this	miRNA,	successfully	decreased	the	 level	of	miR-218	and	restored	expression	of	EAAT2.	
The	authors	also	report	that	silencing	miR-218	had	a	normalising	effect	on	the	expression	of	
connexin	 43	 and	 glial	 acidic	 fibrillary	 protein	 (GFAP),	 indicating	 that	 this	microRNA	might	
have	a	wider	role	in	modulating	glial	activation.	Consistent	with	the	findings	described	in	this	
paper,	 Morel	 et	 al.	 had	 previously	 identified	 an	 exosome-secreted	miRNA	 that	 displayed	 a	
similar	 function	 to	 that	 described	 here	 for	 miR-218,	 regulating	 EAAT2	 expression	 in	 glia	
(Morel	et	al.,	2013).	
	
Hoye	et	al.	 build	 on	previous	 evidence,	 collected	mainly	 from	mutant	 SOD1	 rodent	models,	
showing	that	ALS	is	a	multiphasic	disease,	where	onset	is	determined	by	pathophysiological	
changes	in	motor	neurons	and	progression	is	characterized	by	alteration	of	glial	function	(Sun	
et	al.,	2015).	However,	 in	vitro	models	of	ALS	(Hautbergue	et	al.,	2017),	as	well	as	models	of	
inflammation	independent	of	SOD1	(Frakes	et	al.,	2014),	show	that	glial	cells	can	indeed	drive	
motor	neuron	loss	if	they	harbour	intrinsic	abnormalities.				
	
Growing	 evidence	 is	 emerging	 that	 miRNAs	 released	 by	 astrocytes	 via	 exosomes	 or	
complexed	with	proteins,	are	 important	regulators	of	neuron-astrocyte	cross-talk	as	well	as	
synaptic	function	and	stability.	Recently,	Chaudhuri	et	al.	demonstrated	how	the	presence	of	
inflammatory	 signals	modifies	 the	miRNA	 cargo	 of	 astrocyte-secreted	 extracellular	 vesicles	
and	 how	 these	 regulate	 neurotrophic	 signalling	 to	 neurons	 (Chaudhuri	 et	 al.,	 2018).	 The	
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concept	 that	 some	 of	 these	 secreted	miRNAs	 are	 then	 circulated	 in	 the	 CSF	 and	 can	 act	 as	
long-distance	signalling	molecules	underpinning	disease	propagation,	is	supported	by	several	
studies	 that	have	 identified	 in	CSF	miRNAs	 involved	 in	 the	 regulation	of	 neuronal	 and	glial	
activity	(Waller	et	al.,	2017).			
	
From	 a	 therapeutic	 perspective,	 miRNAs	 are	 known	 to	 affect	 multiple	 mRNA	 transcripts	
simultaneously,	which	has	 implications	 for	unwanted	off-target	 effects	 in	vivo.	miRNAs	also	
have	varying	targets	in	different	cell	types	and,	as	Hoye	et	al.	highlight	in	their	discussion,	full	
ablation	 of	 miR-218	 leads	 to	 motor	 neuron	 degeneration.	 Thus,	 attempting	 to	 ameliorate	
astrocyte	dysfunction	in	ALS	by	lowering	the	expression	of	miR-218	globally	within	the	CNS	
would	be	likely	to	have	adverse	off-target	effects	on	motor	neuron	health.		
	
The	 pathophysiological	 changes	 contributing	 to	 neuronal	 injury	 and	 perturbation	 of	 glial	
function	 in	 ALS	 are	 complex	 and	 effective	 therapeutic	 approaches	 are	 likely	 to	 require	
targeting	 of	 multiple	 effectors	 simultaneously.	 Previous	 approaches,	 aiming	 to	 inhibit	 or	
activate	a	single	target,	have	failed	to	deliver	substantial	impact	on	ALS	disease	progression	in	
the	clinic.	Astrocyte	involvement	in	ALS	is	characterised	by	a	complex	gain	of	toxic	properties	
as	well	as	loss	of	neuroprotective	functions,	resulting	in	an	aberrant	cellular	phenotype	which	
is	 unlikely	 to	 be	 corrected	 by	 manipulation	 of	 a	 single	 target.	 In	 this	 context,	 engineered	
miRNA-like	 molecules	 with	 selective	 cellular	 targeting	 and	 a	 strong	 safety	 profile	 would	
represent	useful	tools	in	the	effort	to	normalise	multiple	facets	of	the	cellular	pathophysiology	
underlying	 ALS.	 Hoye	 and	 colleagues	 have	 elegantly	 dissected	 through	 in	 vitro	 and	 in	 vivo	
studies	one	molecular	mechanism	contributing	to	the	perturbed	cross-talk	between	neurons	
and	astrocytes	in	models	of	ALS	(Figure	1).	miR-218	has	not	so	far	emerged	as	a	prominent	
candidate	 in	 studies	 of	 the	 expression	 of	 microRNAs	 in	 human	 biosamples	 (Waller	 et	 al.,	
2017)	and	further	work	is	required	to	ascertain	the	importance	of	this	pathway	in	relation	to	
human	ALS.	
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Figure	1.	Schematic	of	the	proposed	impact	of	miR-218	in	ALS	pathology.	
A)	 The	 SOD1	 G93A	mouse	model	 of	 ALS	mimics	 some	 of	 the	major	 clinical	 aspects	 of	 the	
human	disease.	Prior	to	adulthood	mutant	SOD1	mice	are	pre-symptomatic	and	do	not	display	
clear	signs	of	motor	impairment.	Between	70–90	days,	depending	on	the	genetic	background,	
the	 mice	 start	 displaying	 signs	 of	 denervation	 and	 progressive	 motor	 neuron	 (MN)	 loss,	
including	tremors,	splay	reflex	defects	and	 loss	of	grip	strength.	They	then	quickly	progress	
towards	paralysis,	when	they	are	euthanized.	At	the	cellular	level	(B),	pre-symptomatic	mice	
do	not	display	major	signs	of	motor	neuron	loss	or	gliosis,	which	only	become	evident	at	the	
symptomatic	and	end	stages	of	the	disease.	Hoye	et	al.	propose	and	partly	demonstrate	that	
release	 of	miR-218	 from	 dying	 neurons	 drives	 loss	 of	 the	 astrocytic	 glutamate	 transporter	
(EAAT2/Glt1),	which	contributes	to	excitotoxicity	and	exacerbates	the	inflammatory	reaction	
of	 astrocytes	 surrounding	 the	motor	neurons.	This	 cascade	of	 events	 spirals	 in	 a	 toxic	 loop	
that	impairs	astrocyte	function	and	exacerbates	motor	neuron	loss	and	gliosis.	
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Glossary	
Non-coding	RNA:	untranslated	RNA	species	contributing	to	the	post-transcriptional	control	
of	protein	synthesis	via	binding	and	subsequent	inhibition	of	mRNA	translation	
	
RILES	 or	 RNAi-Inducible	 Luciferase	 Expression	 System:	 a	 plasmid-based	 system	
engineered	 to	monitor	 the	 activity	 of	 endogenous	 RNAi	machinery.	 The	miRNA	 of	 interest	
suppresses	 the	expression	of	a	 transcriptional	 repressor	and	consequently	 switches	ON	 the	
expression	of	a	luciferase	reporter	gene.	
	
